31684-14-7

Basic information

• Product Name: Benzene, 1,2-bis(bromomethyl)-4-chloro-
• CAS NO: 31684-14-7
• Molecular Formula: C8H7Br2Cl
• Molecular Weight: 298.405
• Mol File: 31684-14-7.mol
• Article Data: 16

Chemical Properties

• CAS DataBase Reference: Benzene, 1,2-bis(bromomethyl)-4-chloro-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzene, 1,2-bis(bromomethyl)-4-chloro-(31684-14-7)
• EPA Substance Registry System: Benzene, 1,2-bis(bromomethyl)-4-chloro-(31684-14-7)

Safety Data

• Hazardous Substances Data: 31684-14-7(Hazardous Substances Data)

Upstream product

• 118-45-6 4-chlorophthalic anhydride 
• 110706-49-5 4-chloro-2-(hydroxymethyl)benzyl alcohol 
• 7789-60-8 phosphorus tribromide 
• 95-64-7 4-amino-o-xylene 
• 615-60-1 4-chloro-1,2-dimethylbenzene 
• 7726-95-6 bromine 

Downstream Products

• 1092445-88-9 2-(2-cyclobutyloxy-3-methyl-benzoylamino)-5-chloro-indan-2-carboxylic acid 
• 1092448-45-7 2-(2-cyclobutyloxy-3-methyl-benzoylamino)-5-chloro-indan-2-carboxylic acid ethyl ester 
• 127168-76-7 5-chloro-2,3-dihydro-1H-isoindole 
• 1425091-68-4 C₁₉H₂₂ClNO₂ 
• 1616788-05-6 5-chloro-2-(3-phenylprop-2-yn-1-yl)isoindoline 
• 127168-77-8 5-chloro-2-p-tosylisoindoline 
• 259807-60-8 1-benzyl-4-[(5-chloroisoindol-2-yl)sulfonyl]piperazine 
• 19725-81-6 4-chlorohomophthalic acid 
• 22479-38-5 4-chloro-1,2-bis-cyanomethyl-benzene 

Relevant articles and documents

THIENODIAZEPINE DERIVATIVES AND APPLICATION THEREOF

The present invention relates to a class of thienodiazepine derivatives and an application thereof in the preparation of a drug for the treatment of diseases associated with bromodomain and extra-terminal (BET) Bromodomain inhibitors. Specifically, the present invention relates to compounds represented by formulas (I) and (II), as well as pharmaceutically acceptable salts thereof.

IDO/TDO Inhibitor

A compound of formula (I) given below or a pharmaceutically acceptable salt of the compound is useful as an IDO/TDO inhibitor. Thus, the compound of formula (I) or the pharmaceutically acceptable salt of the compound can be used as, for example, a therapeutic agent for a disease or a disorder selected from tumor, infectious disease, neurodegenerative disorder, cataract, organ transplant rejection, autoimmune disease, postoperative cognitive impairment, and disease related to women's reproductive health [in the following formula (I), ring A represents an aromatic ring, an aliphatic ring, a heterocyclic ring, or a condensed ring of two or more rings selected from an aromatic ring, an aliphatic ring and a heterocyclic ring; X, R1 and R2 represent a substituent on a ring atom constituting ring A; m represents an integer of 0 to 6; X represents, for example, a halogen atom; and R1 and R2 are the same or different and are selected from, for example, the group consisting of groups of formula (a) or formula (b); and in the following formula (a) and formula (b), Y is selected from the group consisting of O, S, and Se, Z is selected from the group consisting of O, S, and Se, n represents an integer of 1 to 8, r represents an integer of 1 to 8, s represents an integer of 1 to 8, R4 represents, for example, —C(═NH)—HN2, and R6 represents, for example, a substituted or unsubstituted aryl group].

PHARMACEUTICAL COMPOUNDS

The invention provides a compound for use in medicine, the compound being a compound of the formula (VI0) or a salt, solvate, tautomer or N-oxide thereof: wherein the bicyclic group: is selected from the structures C1, C5 and C6: wherein n is 0, 1, 2 or 3; R1 is hydrogen, hydroxy, or O—Rz; R2a is hydroxy, methoxy or O—Rz; provided that at least one of R1 and R2a is O—Rz; Rz is Lp-Rp1; SO3H; a glucuronide residue; a mono-, di- or tripeptide residue; or Lp is a bond, C═O, (C═O)O, (C═O)NRp1 or S(O)xNRp1; x is 1 or 2; Rp1 is hydrogen or a an optionally substituted C1-25 hydrocarbyl group containing 0, 1 or 2 carbocyclic rings and 0, 1, 2, 3, 4, 5 or 6 carbon-carbon multiple bonds, provided that Rp1 is not hydrogen when Lp is a bond, C═O or (C═O)O; and provided also that O—Rz does not contain an O—O moiety; and excluding compounds wherein R1 is hydroxy and R2a is methoxy; Rp2 and Rp3 are the same or different and each is a group Rp1; and R3, R4a, R8 and R10 are defined in the claims. The compounds of formula (VI0) are pro-drugs of parent compounds wherein R1 and/or R2a are hydroxy, wherein the parent compounds have Hsp90 inhibiting activity.